For providers
Offer hope backed by results: the FDA-cleared precision therapy that delivers a 79% remission rate from depression in just five days.
A new era in brain health is here.
SAINT® Depression Therapy is accelerated, fMRI-guided TMS designed to target each patient’s unique brain circuitry, helping clinicians achieve faster, more durable outcomes.
SAINT
ECT
TMS
Esketamine
Medication
Data are shown for open-label studies in moderately to severely treatment-resistant depression. References: Cole et al 2020 (SAINT), Heijnen et al 2010 (ECT), Thirthalli et al 2020 (ECT), Blumberger et al 2018 (TMS 32%), Hsu et al 2019 (TMS 17)%; Janik et al 2025 (Esketamine 16%) Marton et al 2024 (Esketamine 37%, time to remission); Zaki et al 2025 (Esketamine treatment window); Sub-analysis of Blumberger participants with similar treatment resistance to SAINT patients), Rush et al 2006 (pharmacotherapy), Liu et al 2021 (pharmacotherapy, treatment window)
Treating depression in days, not weeks.
SAINT is an advanced, targeted form of TMS therapy that uses precision neuromodulation to deliver rapid and lasting remission from Major Depressive Disorder (MDD) in an accelerated, 5-day treatment.
SAINT helps people get better, faster.
Unlike conventional treatments that can take weeks or months to start working, SAINT can bring remission from depression symptoms in days.
0
days of noninvasive, non-drug treatment (versus 6-9 weeks for standard TMS).
0 %
of trial participants entered remission from their depression.
0
days to remission on average instead of weeks or months.
0
clinic visits (versus 30-36 for standard TMS).
0
days of noninvasive, non-drug treatment (versus 6-9 weeks for standard TMS).
0 %
of trial participants entered remission from their depression.
0
days to remission on average instead of weeks or months.
0
clinic visits (versus 30-36 for standard TMS).
Cole EJ, Stimpson KH, Bentzley BS, et al.: Stanford Accelerated Intelligent Neuromodulation Therapy for treatment-resistant depression. Am J Psychiatry 2020; 177:716–726 2.Cole EJ, Phillips AL, Bentzley, BS, et al.: Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. Am J Psychiatry 2021; 179:2, 132–141.
Featured resources
Discover the science and clinical data that show the power of SAINT.
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression
Proven results, genuine hope, and a new way forward.
SAINT is here to change the timeline for recovery, offering a new path grounded in precision science and proven to deliver rapid remission from depression.
Rapid remission
Clinical trials show a 79% remission rate in just 5 days of treatment, significantly shortening the road to lasting recovery.
Personalized treatment
SAINT uses fMRI-guided targeting to map unique brain circuitry, ensuring a precise and tailored approach that is not one-size-fits-all.
Relief without medication
SAINT is a noninvasive therapy designed to target the brain’s neural circuitry without the use of medication.
Noninvasive outpatient therapy
The treatment delivers gentle, well tolerated magnetic pulses to the brain without requiring anesthesia or invasive surgery.
Scientific rigor
Our precision treatment is built on groundbreaking science, giving people a proven path forward with unparalleled confidence.
What people are saying about SAINT
Discover how science and compassion come together through the voices of patients and clinicians who’ve experienced SAINT firsthand.
Frequently asked questions
-
SAINT is an accelerated form of transcranial magnetic stimulation (TMS), but has some key differences.
- Speed: SAINT condenses treatment into only 5 days, versus 6–9 weeks with conventional TMS. On average, participants reached remission in just 2.6 days rather than 3.5 weeks.
- Personalization: SAINT is the only FDA-cleared depression treatment that uses functional MRI (fMRI) brain imaging to identify a personalized target for stimulation to treat major depression.
- Precision: The combination of the fMRI, a personalized target, and neuronavigation enable SAINT to use best-in-class precision targeting.
- Effectiveness: With over 400 patients treated in clinical trials, SAINT relieved symptoms for 85% of participants, with no serious adverse events.
-
Insurance coverage for SAINT is currently limited but we are working to expand it.
- Medicare Fee-for-Service (FFS):
Approved for payment at Verified SAINT Provider hospital sites. - Medicare Advantage (MA), Commercial, and Medicaid Plans:
Coverage is determined on a case-by-case basis through the prior authorization process. Your provider can assist in submitting the necessary documentation and requesting approval from your insurer. - Out-of-Pocket:
Self-pay options are available. Pricing and payment plans vary by site, so please contact your preferred treatment provider directly for details.
- Medicare Fee-for-Service (FFS):
-
Candidates for SAINT are adults that have been diagnosed with Major Depressive Disorder and medications like antidepressants have not helped.
Please contact a verified SAINT location to meet with a physician regarding your eligibility.
-
SAINT treatment is generally well-tolerated. The most commonly reported side effects are mild headache and temporary scalp irritation at the treatment site. Your SAINT provider will assist you in resolving any discomfort experienced during your treatment.
